PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
暂无分享，去创建一个
A. Broeks | K. Mertz | G. Meijer | E. Smit | K. Hummelink | M. M. van den Heuvel | V. van der Noort | K. Monkhorst | W. Theelen | M. Muller | D. Peters | D. Thommen | V. Koelzer | A. Zippelius | F. Lalezari | R. Schouten | J. Haanen | T. Schumacher